ETRA · MRNA in the 13F filings
Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.
Holders over time
- ETRA
- MRNA
| Quarter | ETRA | MRNA |
|---|---|---|
| Q4 2020 | none listed holders, n.a. | 16 holders, $4.4bn |
| Q1 2021 | none listed holders, n.a. | 18 holders, $8.0bn |
| Q2 2021 | none listed holders, n.a. | 22 holders, $18.4bn |
| Q3 2021 | none listed holders, n.a. | 27 holders, $27.6bn |
| Q4 2021 | none listed holders, n.a. | 20 holders, $17.2bn |
| Q1 2022 | none listed holders, n.a. | 16 holders, $11.8bn |
| Q2 2022 | none listed holders, n.a. | 19 holders, $10.2bn |
| Q3 2022 | none listed holders, n.a. | 22 holders, $8.4bn |
| Q4 2022 | none listed holders, n.a. | 20 holders, $13.0bn |
| Q1 2023 | none listed holders, n.a. | 17 holders, $11.2bn |
| Q2 2023 | none listed holders, n.a. | 15 holders, $8.9bn |
| Q3 2023 | none listed holders, n.a. | 12 holders, $7.2bn |
| Q4 2023 | none listed holders, n.a. | 8 holders, $6.9bn |
| Q1 2024 | none listed holders, n.a. | 7 holders, $7.6bn |
| Q2 2024 | none listed holders, n.a. | 13 holders, $9.5bn |
| Q3 2024 | none listed holders, n.a. | 12 holders, $4.8bn |
| Q4 2024 | none listed holders, n.a. | 15 holders, $3.1bn |
| Q1 2025 | none listed holders, n.a. | 11 holders, $2.0bn |
| Q2 2025 | none listed holders, n.a. | 10 holders, $2.0bn |
| Q3 2025 | none listed holders, n.a. | 9 holders, $1.2bn |
| Q4 2025 | none listed holders, n.a. | 10 holders, $2.5bn |
| Q1 2026 | none listed holders, n.a. | 9 holders, $4.8bn |
| Q2 2026 | none listed holders, n.a. | 9 holders, $8.0bn |
| Q3 2026 | 2 holders, $20m | 17 holders, $22.4bn |
Electra Therapeutics Inc
- Holders
- 0
- Reported value
- $0
- Buyers
- n.a.
- Sellers
- n.a.
No cross-section for this quarter.
Moderna Inc
- Holders
- 13
- Reported value
- $9.5bn
- Buyers
- 9
- Sellers
- 4
Breadth +5 among 94 comparable managers.
Who holds both, Q2 2024
Both (0)
No tracked manager lists every one of them.
Only ETRA (0)
None.
Only MRNA (13)
ARK Investment Management LLC, Baillie Gifford & Co, Capital World Investors, Fidelity (FMR LLC), Invesco Ltd, Jane Street Group LLC, Man Group PLC, PDT Partners LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Wellington Management Group LLP, Winton Group Ltd
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.